Eli Lilly and AstraZeneca Collaborate on Immuno-Oncology Trial

Strategic Insights -

Eli Lilly and Company has entered into a clinical trial collaboration with AstraZeneca to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA (ramucirumab), Lilly's VEGF Receptor 2 antiangiogenic cancer medicine. The Phase I study aims to establish the safety and a recommended dosing regimen for the combination of MEDI4736 and ramucirumab in patients with advanced solid tumors. The collaboration has the potential to provide new cancer treatment solutions and marks the next wave of immuno-oncology research.

Key Takeaways:

  • The partnership will evaluate the combination of MEDI4736 and ramucirumab in patients with advanced solid tumors in a Phase I study.
  • The study aims to establish the safety and a recommended dosing regimen for the combination therapy.
  • The collaboration marks a significant step in the development of immuno-oncology research and the potential to transform cancer treatment.
  • MEDI4736 is a monoclonal antibody that targets programmed cell death ligand 1 (PD-L1), while ramucirumab is a VEGF Receptor 2 antagonist.
  • Preclinical data indicate that combining VEGFR inhibitors with immune checkpoint blockades has the potential to enhance anti-tumor activity.
  • The collaboration represents the next wave of immuno-oncology research, bringing together two innovative medicines to explore novel combination therapies.

Statistics:

  • The Phase I study will assess the combination of MEDI4736 and ramucirumab in patients with advanced solid tumors.
  • The study aims to establish the safety and a recommended dosing regimen for the combination therapy.
  • 2015 marked a significant year in the development of immuno-oncology research, with the potential to transform the way cancer is treated.
  • The collaboration between Eli Lilly and AstraZeneca is a major step forward in the development of combination therapies in immuno-oncology.

Sources:

  • NewsRx, June 17, 2015
  • Eli Lilly and Company
  • AstraZeneca